Skip to content
 

SmallCap Round Up: Star Phoenix, MyHealthChecked, Kibo Energy

*

London’s AIM Index appears on course for a positive finish for the first time this week, although the market is well off mid session highs. With just a few minutes to the bell, the index sat up less than one point at 809.88

  • Star Phoenix +27%
  • MyHealthChecked +20%
  • Kibo Energy +15%
  • Mirada -61%
  • Fusion Antibodies -16%

Heading into the close and oilfield services company Star Phoenix [LON:STA] was the day’s biggest riser, adding 27% by the bell. However this is a relative minnow, dealflow was incredibly light and the spread was being quoted at in excess of 11%, consuming much of the upside.


MyHealthChecked [LON:MHC] advanced 20% on the day in the wake of news that it would launch an extended range of test at home products via Boots. A total of 20 different kits will be launched, including six which operate on a lateral flow basis, with management noting this marks a turning point when it comes to consumer demand for at-home testing.

Kibo Energy [LON:KIBO] advanced 15% on the day, having published a pair of updates this morning. One highlighted the fact that a wholly owned UK subsidiary had concluded heads of terms with an investor consortium, which includes the reprofiling of existing loans and a significant cash injection into the business.

Mirada [LON:MIRA] was the worst performer on the day, falling some 61% off the back of news that the company plans to delist from AIM and move over to the JP Jenkins platform. Given the significant holdings of a single shareholder here, the motion will be passed. A trading update included with the note showed revenues and EBITDA posting modest year on year declines, but debts exceeded the $10m mark.

Fusion Antibodies [LON:FAB] slipped 16%, although volumes were far from remarkable and order flow was lumpy. There’s no formal news out although in recent years a trading update has been supplied in early May.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
Pepperstone
WisdomTree
CME Group
Back To Top